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Abstract
Introduction: Polycystic ovary syndrome (PCOS) is one of the commonest endocrinopathies. Clinically it can present as oligo-/amenor-
rhoea, hyperandrogenism and/or fertility problems.
Material and methods: The study involved 60 women admitted to the Department of Internal Medicine and Endocrinology at the Medical 
University of Warsaw. The initial evaluation, including case history and two-dimensional vaginal ultrasound, was performed by gynae-
cologists. All hormonal investigations (fT, free testosterone; bioT, bioavailable testosterone; T, total testosterone; T EQ, free testosterone by 
equilibrium dialysis; A, androstenedione; A EQ, free androstenedione by equilibrium dialysis; salA, salivary androstenedione; salT, salivary 
testosterone) were performed. Anthropometrical data, excess facial and body hair, acne, and menstrual cycle frequency were also assessed.
Results: Increased levels of T, fT, T EQ and A were noted in 20.0%, 89.8%, 100% and 28.3% of women, respectively. A very high correla-
tion was found between salivary androstenedione and free androstenedione estimated by EQ in plasma (p < 0.05, r = 0.67), and total 
androstenedione in plasma (p < 0.05, r = 0.71). Correlation between salT and T was r = 0.31, p < 0.05 and salT and T EQ was r = 0.26, 
p = 0.04. Correlation between salA/salT and T, A in plasma (respective values r = 0.39 and r = 0.28, p < 0.01) and between salA/salT and 
A EQ, T EQ (respectively r = 0.34 and r = 0.48, p < 0.01) was evident.
Conclusions: SalA/salT ratio may be a good indicator of hyperandrogenism in women. We also confirm that measurement of androstene-
dione in plasma may be useful in making a diagnosis of PCOS. (Pol J Endocrinol 2012; 63 (3): 183–190)
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Streszczenie
Wstęp: Zespół policystycznych jajników (PCOS) jest jedną z najczęstszych endokrynopatii. Charakteryzuje się zaburzeniami 
miesiączkowania o charakterze rzadkich miesiączek, niepłodnością, hiperandrogenizmem.
Materiał i metody: Do badania włączono 60 kobiet hospitalizowanych w Klinice Chorób Wewnętrznych i Endokrynologii Warszawskiego 
Uniwersytetu Medycznego. Przeprowadzono badanie podmiotowe i przedmiotowe, łącznie z badaniem ultrasonograficznym narządu 
rodnego. Analizie poddano panel badań hormonalnych (fT, wolny testosteron; bioT, testosteron biodostępny; T, całkowity testosteron; 
T EQ, wolny testosteron wyznaczony metodą dializy równowagowej; A, androstendion; A EQ, wolny androstendion wyznaczony metodą 
dializy równowagowej; salA, androstendion w ślinie; salT, testosteron w ślinie) wykonanych w godzinach porannych, między 3. a 6. dniem 
cyklu. Oceniano parametry antropometryczne, stopień hirsutyzmu oraz charakter cyklów miesiączkowych.
Wyniki: Podwyższone stężenie androgenów: T, fT, T EQ i A odnotowano u 20,0, 89,8, 100,0 i 28,3% badanych kobiet. Odnotowano wysoką 
korelację między salA i A EQ (p < 0,05, r = 0,67) i A (p < 0,05, r = 0,71). Korelacja między salT i T wynosiła r = 0,31, p < 0,05 oraz salT 
i T EQ była równa r = 0,26, p = 0,04. Wykazano zależność pomiędzy salA/salT oraz T, A (odpowiednio r = 0,39 i r = 0,28, p<0,01) oraz 
między salA/salT i A EQ, T EQ (odpowiednio r = 0,34 i r = 0,48, p < 0,01).
Wnioski: Wydaje się, że oznaczanie wskaźnika salA/salT może być dobrym wyznacznikiem hiperandrogenizacji u kobiet. Ocena stężenia an-
drostendionu w surowicy u kobiet może być pomocna w diagnostyce zespołu hiperandrogenizacji u kobiet. (Endokrynol Pol 2012; 63 (3): 183–190)
Słowa kluczowe: zespół policystycznych jajników, androgeny w ślinie, hiperandrogenizm, zaburzenia miesiączkowania
Introduction
Polycystic ovary syndrome (PCOS) is one of the com-
monest endocrinopathies, affecting about 4–7% of 
women of reproductive age [1, 2]. Clinically it is pre-
sented as oligo-/amenorrhoea, clinical and/or laboratory 
hyperandrogenism, and/or fertility problems [1–3]. 
According to the ESHRE/ASMR consensus, PCOS can 
be diagnosed when a woman fulfills at least two out of 
three criteria: oligo/anovulation, clinical or biochemical 
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hyperandrogenism, and/or polycystic ovaries found by 
ultrasound imaging, after exclusion of other causes of 
menstrual irregularities and hyperandrogenaemia [4]. 
Hyperandrogenism is manifested by hirsutism, per-
sistent acne, alopecia and biochemical abnormalities, 
such as increased levels of total (T) and free testoster-
one (fT) [5–7]. Hyperandrogenaemia in PCOS can be 
assessed in various ways. Commonly, this is done by 
measuring the level of T and/or fT and sex hormone 
binding globulin (SHBG) and calculating the bioavail-
able fraction using free androgen index (FAI) or mass 
equation [8, 9]. Synthesised in the adrenal cortex and 
ovarian theca cells, androstenedione (A) may be also 
used to diagnose hyperandrogenaemia. However, 
only a few prospective studies on androstenedione 
in PCOS are available [10]. Dehydroepiandrosterone 
(DHEA) derived from the adrenal glands, has limited 
diagnostic value. It requires accurate and sensitive assay 
which cannot be achieved because of its diurnal var-
iations and technological difficulties [11]. Nevertheless, 
DHEA sulfate (DHEAS) has been widely used, mainly 
as a marker for adrenal androgen excess, because it is 
almost exclusively synthesised in the adrenal cortex. 
Additionally, its level is stable throughout the day and 
the menstrual cycle, making it easily measured [12]. 
Peripheral androgen synthesis may also contribute 
to hyperandrogenism in PCOS [13, 14]. Testosterone 
level is important in the diagnosis and management of 
a number of diseases or syndromes in females, includ-
ing precocious puberty, androgen-secreting tumours, 
and PCOS [15]. However, there are several limitations 
to their use. Most measurements based on immunoas-
says are not designed or validated for the relatively low 
levels normally presented in women [9]. Moreover, the 
range considered as normal, not changing with age, is 
broad and includes also hyperandrogenic women, even 
those with severe hirsutism [16].
All these factors raise questions about the diagnos-
tic value of testosterone level measurement in women 
with hyperandrogenism [16]. In 20–40% of patients 
with PCOS, serum analysis fails to identify biochemi-
cal hyperandrogenism [17]. Most testosterone assays 
show poor sensitivity and accuracy in the female 
ranges, which, even when elevated under conditions 
such as PCOS, still tend to be well below normal male 
ranges [18]. Additionally, circulating levels in females 
vary according to reproductive maturity, phase of the 
menstrual cycle, time of day, and feeding [19]. There 
are no age and gender normal ranges, and in fact there 
is no testosterone standard on which an assay could be 
based [20]. Other steroids with similar configurations 
may cross-react with the antibody used in immunoassay. 
Methods that improve the performance of testosterone 
immunoassays, such as extraction of testosterone and 
chromatographic purification before the assay, are not 
supposed to be used in a commercial setting. From the 
other side, simpler immunoassay methods such as direct 
RIA or ELISA are criticised because of poor accuracy in 
the female range or the overestimation of results [19]. 
Measurement of total testosterone by mass spectro-
metry has been recommended as an alternative to avoid 
the above mentioned problems [21]. Unfortunately, 
the method is slower and more expensive than RIA. 
Salivary testosterone represents the unbound serum 
fraction, therefore levels are much lower than those in 
serum [22].
The aim of this study was to determine the useful-
ness of salivary androgens as a new diagnostic tool 
and to evaluate their applicability for the diagnosis of 
women with PCOS.
Material and methods
The study involved 60 women admitted to the Depart-
ment of Internal Medicine and Endocrinology at the 
Medical University of Warsaw. All women, characterised 
in Table I, included in the study fulfilled the Rotterdam 
criteria [4]. The exclusion criteria included: hyperpro-
lactinaemia, congenital adrenal hyperplasia, thyroid 
disease, other causes of amenorrhea such as premature 
ovarian failure, Cushing’s syndrome, and androgen-se-
creting tumour. No subject was on study medication 
at the time of assay. The protocol was approved by the 
local ethics committee, and written informed consent 
was obtained from each patient. The initial evaluation, 
including case history and two-dimensional vaginal 
ultrasound, was performed by gynaecologists. All hor-
monal investigations were performed after an overnight 
fast, between the third and sixth day of either a sponta-
neous or a progestagen-induced menstruation (in the 
latter case menstrual bleeding was typically obtained 
after ten-day administration of dydrogesterone (Du-
phaston®). Blood samples for endocrine measurements 
were obtained between 7.30 am and 8.30 am and stored 
Table I. Anthropometric data in PCOS women
Tabela I. Dane antropometryczne badanych kobiet z PCOS
Anthropometric data Mean ± SD (n = 60) 
Age [years] 28.69 ± 5.23
BMI [kg/m2] 25.04 ± 6.78
WHR 0.80 ± 0.06
SBP [mm Hg] 117.12 ± 12.12
DBP [mm Hg] 73.62 ± 8.97
BMI — body mass index; WHR — waist to hip ratio; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; SD — standard deviation
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Table II. Hormonal characteristics of women with PCOS
Tabela II. Charakterystyka hormonalna badanych kobiet 
z PCOS
Hormonal tests Mean value ± SD, n = 60
T [ng/mL] 0.66 ± 0.32
sal T [pg/mL] 90.81 ± 25.71
fT [pg/mL] 10.34 ± 6.63
fT [%] 1.57 ± 0.52
FAI 6.6 ± 5.97
bioT [pg/mL] 258.47 ± 165.42
bioT [%] 39.23 ± 12.75
T EQ [pg/mL] 42.7 ± 27.09
T EQ [%] 6.19 ± 1.50
DHEA-S [μg/dL] 312.38 ± 128.4
A [ng/mL] 4.34 ± 1.85
sal A [pg/mL] 391.91 ± 173.29
A EQ [pg/mL] 1,069.64 ± 506.3
A EQ [%] 24.66 ± 6.74
T — total testosterone; salT — salivary testosterone; fT — free 
testosterone; FAI — free androgen index; bioT — bioactive testosterone; 
T EQ — free testosterone by equilibrium dialysis; DHEA-S — 
dehydroepiandrosterone sulfate; A — androstendione; salA — salivary 
androstendione; A EQ — free androstenedione by equilibrium dialysis;  
SD — standard deviation; n — number of patients
at –80 °C until assayed. Age, height, body weight, body 
mass index (BMI), excess facial and body hair, acne, and 
menstrual cycle frequency were also assessed. BMI 
was calculated as weight divided by height squared. 
Amenorrhea was defined as absent menstrual bleed-
ing in the past 90 days. Oligomenorrhea was defined 
as more than 35 days between cycles with fewer than 
eight menstrual periods in the past year. Hirsutism was 
assessed according to the Ferriman-Galwey scale [23], 
where a score above eight was considered significant. 
Diagnosis of polycystic ovaries using pelvic ultrasound 
examinations was based on the presence of either 12 
or more follicles measuring 2–9 mm in diameter, or 
increased ovarian volume (> 10 cm3) [24]. fT and bioT 
were carried out using the formula available on the 
website of the International Society for the Study of the 
Ageing Male (ISSAM) (http://www.issam.ch/freetesto.
htm) from concentrations of T, SHBG and albumin val-
ues measured in the same sample from each woman. 
This method is described in detail by Vermeulen et al. 
[25]. Free testosterone and free androstenedione levels 
in serum were measured by an equilibrium dialysis 
(T EQ, A EQ). Equilibrium dialysis was carried out to as-
sess free testosterone and free androstenedione fraction 
using a 96-well Equilibrium Dialyser, Membrane MWCO 
5 kDa (Harvard Apparatus, USA) [26]. Radioactive tes-
tosterone (PerkinElmer, Life and Analytical Sciences, 
USA) or androstenedione (American Radiolabelled 
Chemicals, Inc, USA) respectively was used as a tracer. 
Tracers were thin-layer purified (HPTLC-Alu Silica Gel 
60) according to the manufacturer’s instruction using 
toluene:ethyl acetate 2:1, and used no longer than one 
month after purification. Serum was diluted 1:1 with 
0.9% saline solution, with 30 kBq/ml of tracer added. 
Samples were incubated for 30 min at 37 °C with agita-
tion. Immediately, 290 microlitres of sample was trans-
ferred to the appropriate compartment of the dialyser 
with opposite cell filled with 290 microlitres of saline so-
lution. Equilibrium was reached during dialysis within 
20 hours at 37 °C with gentle agitation. Subsequently, 
radioactivity of samples from each compartment was 
measured. Free Androgen Index (FAI) was measured as 
a ratio of the total testosterone concentration divided 
by the SHBG level. Endocrine investigations involved 
luteinising hormone (LH), follicle-stimulating hormone 
(FSH), oestradiol, total testosterone (T), DHEAS, thyro-
trophin-stimulating hormone (TSH), insulin, and SHBG 
being measured by electrochemiluminescence immuno-
assays (Roche Diagnostics, Germany) using an Elecsys 
20l0 analyser (Hitachi, Japan). Androstenedione (A) 
and 17-OH-progesterone (17-OH-P) concentrations 
were measured by chemiluminescence immunoassays 
(Siemens Healthcare Diagnostics Products Ltd, UK) 
using Immulite 2000. Salivary testosterone (sal T) and 
androstenedione (sal A) were measured using enzyme 
immunoassay kits (Salimetrics, USA).
All statistical analyses were performed using Sta-
tistica 9.0 software. Data was presented as mean and 
standard deviation (± SD). Correlations between an-
drogens in women with PCOS were tested by analysis 
of covariance (ANOVA test). Depending on distribu-
tion characteristics of the analysed parameters, we 
employed either a t-test in cases of normal distribution 
or a Mann-Whitney test if distribution characteristics 
were not normal. Correlation analysis was performed 
by means of the Pearson rank correlation method. Sta-
tistical significance was assumed for p < 0.05.
Results
Androgen concentrations in PCOS women are shown 
in Table II. Increased levels of T, fT, T EQ, A and DHEA-S 
were noted in 20.0%, 89.8%, 100%, 28.3% and 30.4% 
of women, respectively. More than 27% of women 
(n = 16) showed an elevated (i.e. over 7) concentration 
of FAI. The mean level of SHBG was 47.32 nmol/l. In 
more than 80% of women (n = 49), SHBG concen-
tration was close to the down range. Figure 1 shows 
different concentrations of free androgens measured 
or calculated in women with PCOS by using different 
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diagnostic tools. The level of free testosterone calculated 
was similar to FAI; however, it was about 5-6-fold lower 
than salT, and 4-fold lower than T EQ. The very high 
correlation between salivary androstenedione and free 
androstenedione estimated by EQ in plasma (p < 0.05, 
r = 0.67), and total androstenedione in plasma (p < 0.05, 
r = 0.71) is shown in Figure 2. Figure 3 shows the cor-
relation between salT and T which is r = 0.31, p < 0.01 
and between salT and T EQ which is r = 0.26, p = 0.04. 
A correlation between T and T EQ, and A and A EQ was 
evident: p < 0.01, r = 0.88, p < 0.01, r = 0.85, respec-
tively (Figure 4). Figure 5 shows a correlation between 
salA/salT and total androgens T, A in plasma (respective 
values r = 0.39 and r = 0.28, p < 0.01). Finally, Figure 6 
shows a correlation between salA/salT and A EQ, T EQ, 
which was respectively r = 0.34 and r = 0.48, p < 0.01.
Discussion
Testosterone circulates in blood mostly (98%) as bound 
to serum proteins, primarily to SHBG and albumin. 
Only 1–2% of serum testosterone is free of bounded 
proteins binding [27]. Because SHBG binds T with high 
affinity, the dissociation is very long, so SHBG-bound 
T is not thought to be available for dissociation into 
target tissues for action via classical androgen receptor 
mechanisms [28]. In contrast, albumin binds T with low 
affinity, and its dissociation is rapid [29]. The combina-
tion of weakly albumin-bounded T and free T is referred 
to as bioavailable or non-SHBG-bound T available for 
target tissues to enable androgen action. Using the free 
T by equilibrium dialysis as a gold standard, previous 
studies have evaluated the accuracy of other free and 
bioavailable T assays in men, but only to a limited ex-
tent in women [30–33]. Free T concentration in women 
is approximately 10- or 20-fold lower than T. Because 
oestrogens increase SHBG concentrations and may 
bind to SHBG with high affinity, SHBG level in women 
Figure 1. Comparison of androgen level measured/calculated with 
different methods in PCOS women; salT — salivary testosterone; 
fT — free testosterone calculated; fT EQ — free testosterone by 
equilibrium dialysis; FAI — free androgen index
Rycina 1. Porównanie androgenemii ocenianej różnymi metodami 
u kobiet z PCOS
Figure 2. Pearson’s correlation between salA (pg/mL) and A EQ (pg/mL), p < 0.05, r = 0.67 and salA (pg/mL) and A (ng/mL), 
p < 0.05, r = 0.71; salA — salivary androstendione; A EQ — free androstenedione by equilibrium dialysis; A — androstendione
Rycina 2. Ocena zależności między salA (pg/mL) a A EQ (pg/mL), p < 0,05, r = 0,67 i salA (pg/mL) a A (ng/mL), p < 0,05, r = 0,71 
w korelacji Pearsona
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Figure 3. Pearson’s correlation between salT (pg/mL) and T (ng/mL), p = 0.01, r = 0.31 and salT (pg/mL) and T EQ (pg/mL), 
r = 0.26, p = 0.04; T — total testosterone; salT — salivary testosterone; fT EQ — free testosterone by equilibrium dialysis
Rycina 3. Ocena zależności pomiędzy salT (pg/mL) a T (ng/mL), p = 0,01 r = 0,31 i salT (pg/mL) a T EQ (pg/mL), r = 0,26, p = 0,04 w korelacji 
Pearsona
Figure 4. Pearson’s correlation between T (ng/mL) and T EQ (pg/mL), p < 0.01, r = 0.88 and A (ng/mL) and A EQ (pg/mL), p < 0.01, r = 0.85; 
T EQ — free testosterone by equilibrium dialysis; T — total testosterone; A EQ — free androstenedione by equilibrium dialysis; A — androstendione
Rycina 4. Ocena zależności między T (ng/mL) a T EQ (pg/mL), p < 0,01, r = 0,88 i A (ng/mL) a A EQ (pg/mL), p < 0,01, r = 0,85 w korelacji Pearsona
Figure 5. Pearson’s correlation between salA/salT and T (ng/mL), p < 0.01, r = 0.39 and salA/salT and A (ng/mL), p < 0.01, r = 0.28; 
T — total testosterone; salT — salivary testosterone; salA — salivary androstendione; A — androstendione
Rycina 5. Ocena zależności między salA/salT a T (ng/mL), p < 0,01, r = 0,39 i salA/salT a A (ng/mL), p < 0,01, r = 0,28 w korelacji Pearsona
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is highly variable and affects measurements of total T. 
Calculated free T values were nearly identical to those 
measured by equilibrium dialysis in PCOS women. 
However, the level of calculated fT strongly depends 
on the specific total T and SHBG assays used. Most as-
says for T are immunobased and were not designed or 
validated for the relatively low levels normally present 
in women [9]. Serum analysis fails to identify biochemi-
cal hyperandrogenism in 20–40% of patients with PCOS 
[17]. Every investigator should remember that samples 
for the estimation of plasma levels testosterone should 
be carried out in the morning, before 9 am, in order to 
obviate the effect of the diurnal variation in testosterone 
production. Salivary testosterone offers a non-invasive 
estimation of free testosterone concentration, but there 
does not appear to be an immediate demand for a rou-
tine salivary testosterone service.
It is important to note that free T measured by equi-
librium dialysis requires a sensitive, specific, precise and 
accurate assay for total T. Recent studies have shown that 
the current methods of measurement of total T are not 
sensitive for samples with very low T concentrations, 
such as occur in women, testosterone-deficient men, 
or children. However, sensitivity has been improved 
by new methods based on mass spectrometry [34–36]. 
Furthermore, the free T analogue–based assay should 
not be used in practice because of poorly assessed and 
quality controlled hormone assays [37, 38].
That is why scientists, physicians, investigators, 
clinical chemists, pathologists and editors of medical 
journals insist on better surveillance of assays used in re-
search and patient care. Many women with PCOS were 
not hyperandrogenic at baseline in total testosterone 
assay report. This may be due to a variety of factors. Tes-
Figure 6. Pearson’s correlation between salA/salT and T EQ (pg/mL), p < 0.01, r = 0.34 and salA/salT and A EQ (pg/mL), p < 0.01, 
r = 0.48; T EQ — free testosterone by equilibrium dialysis; salT — salivary testosterone; salA – salivary androstendione; A EQ — free 
androstenedione by equilibrium dialysis
Rycina 6. Ocena zależności między salA/salT a T EQ (pg/ml), p < 0,01 r = 0,34 i salA/salT a A EQ (pg/ml), p < 0,01, r = 0,48 
w korelacji Pearsona
tosterone assays of varying and lesser quality may lead 
to overestimation of the number of normoandrogenic 
women. Our study did not include any healthy women, 
so it is difficult to define sensitivities and specificities of 
specific testosterone levels to make a diagnosis of PCOS. 
Similarly, a multicentre representative cohort of normal 
women would have definitely strengthened the study. 
We therefore examined the correlation between differ-
ent ways of measuring the levels of androgens.
The question is why the amount of testosterone in 
saliva is higher than free level in plasma, in contrast to 
androstenedione. We know that the submandibular 
and parotid glands metabolise the steroids. Intrinsic 
17-ketooxidoreductase activity in the salivary gland 
has already been demonstrated in vitro in several 
species [39–42]. The main metabolites are 20-alpha-hy-
droxy-4-pregnen-3-one for progesterone and andros-
tenedione for testosterone. This is why the progesterone 
and testosterone levels in saliva may not be identical 
with the unbound steroid fraction circulated, because 
a part of the steroids are metabolised by salivary glands 
[43]. However, it has also been suggested that high 
salivary testosterone concentration may result from 
the transfer of a small amount of albumin from plasma 
to saliva [44]. The different ratio in women and men 
makes this hypothesis unlikely given earlier observa-
tions [45–47]. Moreover, the small transfer of 0.1% of 
the plasma proteins does not explain such a difference 
between salivary and plasma hormones concentration 
[48]. That is why metabolism of androgen precursors 
during their passage through the salivary gland may 
be an explanation for this difference. Additionally, it 
was noted in a study of 22 healthy women that the 
ratio of free androstenedione to free testosterone in 
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plasma was about 4-fold the salivary ratio between 
androstenedione and testosterone [49]. This is why we 
support the hypothesis that metabolic conversion of 
testosterone precursors in the salivary gland might be 
added to the value of salivary testosterone measure-
ments as a marker of androgen excess, especially when 
increased peripheral metabolism of such precursors is 
the main mechanism causing hirsutism.
Therefore, we suggest that the best solution is to 
measure salivary androstenedione to salivary testoste-
rone ratio. The correlation between salA/salT and A EQ 
was better (p < 0.01, r = 0.48) than the correlation be-
tween salA/salT and T EQ (p < 0.01, r = 0.34). We found 
a strong correlation between salA and A EQ (r = 0.67). 
Moreover, the assessment of salivary androgens has 
several practical advantages, e.g. non-invasive character, 
repeatability, and simplicity in use.
Conclusions
We conclude that salT and salA may be good indicators of 
hyperandrogenism in women. Our results indicate that 
the salA/salT ratio is a good representation of the clinical 
status of androgenicity. We also confirm that measurement 
of androstenedione in plasma may be useful in making 
a diagnosis of hyperandrogenism in PCOS women.
Founding source
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References
1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The 
prevalence and features of the polycystic ovary syndrome in an unse-
lected population. J Clin Endocrinol Metab 2004; 89: 2745–2749.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 
1223–1236.
3. Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic 
ovary syndrome: clinical, endocrine and ultrasound features in 556 
patients. Clin Endocrinol (Oxf) 1989; 30: 459–470.
4. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop 
Group Revised 2004 consensus on diagnostic criteria and long-term 
health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 
2004; 19: 41–47.
5. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syn-
drome. Lancet 2007; 370: 685–697.
6. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of 
androstenedione by isolated thecal cells from polycystic ovaries. J Clin 
Endocrinol Metab 1994; 79: 1158–1165.
7. Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM. Augmented androgen 
production is a stable steroidogenic phenotype of propagated theca cells 
from polycystic ovaries. Mol Endocrinol 1999; 13: 946–957.
8. Mathur RS, Moody LO, Landgrebe S, Williamson HO. Plasma andro-
gens and sex hormone-binding globulin in the evaluation of hirsute 
females. Fertil Steril 1981; 35: 29–35.
9. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple 
methods for the estimation of free testosterone in serum. J Clin Endo-
crinol Metab 1999; 84: 3666–3672.
10. Azziz R, Carmina E, Dewailly D et al. The Androgen Excess and PCOS 
Society criteria for the polycystic ovary syndrome: the complete task 
force report. Fertil Steril 2009; 91: 456–488.
11. Azziz R, Fox LM, Zacur HA, Parker Jr CR, Boots LR. Adrenocortical 
secretion of dehydroepiandrosterone in healthy women: highly vari-
able response to adrenocorticotropin. J Clin Endocrinol Metab 2001; 
86: 2513–2517.
12. Abraham GE. Ovarian and adrenal contribution to peripheral androgens 
during the menstrual cycle. J Clin Endocrinol Metab 1974; 39: 340–346.
13. Matteri RK, Stanczyk FZ, Gentzschein EE, Delgado C, Lobo RA. An-
drogen sulfate and glucuronide conjugates in nonhirsute and hirsute 
women with polycystic ovarian syndrome. Am J Obstet Gynecol 1989; 
161: 1704–1709.
14. Giagulli VA, Giorgino R, Vermeulen A. Is plasma 5-androstane 3, 17-diol 
glucuronide a biochemical marker of hirsutism in women? J Steroid 
Biochem Mol Biol 1991; 39: 55–61.
15. Matsumoto AM, Bremner WJ. Serum testosterone assays — accuracy 
matters. J Clin Endocrinol Metab 2004; 89: 20–524.
16. Ayala C, Steinberger E, Smith KD, Rodriguez-Rigau LJ, Petak SM. Serum 
testosterone levels and reference ranges in reproductive-age women. 
Endocr Pract. 1999; 5: 322–329.
17. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic 
spectrum of polycystic ovary syndrome: clinical and biochemical 
characterization of the three major clinical subgroups. Fertil Steril 2005; 
83: 1717–1723.
18. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement 
of total serum testosterone in adult men: comparison of current labora-
tory methods versus liquid chromatography-tandem mass spectrometry. 
J Clin Endocrinol Metab 2004; 89: 534–543.
19. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, 
and pitfalls in measuring testosterone: an Endocrine Society position 
statement. J Clin Endocrinol Metab 2007; 92: 405–413.
20. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone 
assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007; 
16: 1713–1719.
21. Thienpont LM, Van Uytfanghe K, Blincko S et al. State-of-the-art of 
serum testosterone measurement by isotope dilution-liquid chroma-
tography-tandem mass spectrometry. Clin Chem 2008; 54: 1290–1297.
22. Vittek J, L’Hommedieu DG, Gordon GG, Rappaport SG, Southren AL. 
Direct radioimmunoassay (RIA) of salivary testosterone, correlation with 
free and total serum testosterone. Life Sci 1985, 37: 711–716.
23. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in 
women. J Clin Endocrinol Metab 1961; 21: 1440–1447.
24. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the 
polycystic ovary: international consensus definitions. Hum Reprod 
Update 2003; 9: 505–514.
25. Vermeulen A, Verdonck L, Kaufmann JM. A critical evaluation of simple 
methods for the estimation of free testosterone in serum. J Clin Endo-
crinol Metab 1999; 84: 3666–3672.
26. Kariv I, Cao H, Oldenburg KR. Development of a high throughput 
equilibrium dialysis method. J Pharm Sci 2001; 90: 580–587.
27. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding 
of 21 endogenous steroids to both testosterone-binding globulin and 
corticosteroid-binding globulin in human plasma. J Clin Endocrinol 
Metab 1981; 53: 58–68.
28. Pardridge WM, Mietus LJ, Frumar AM, Davidson BJ, Judd HL. Effects 
of human sera on transport of testosterone and estradiol into rat brain. 
Am J Physiol 1980; 239: 103–108.
29. Manni A, Pardridge WM, Cefalu W et al. Bioavailability of albumin-bound 
testosterone. J Clin Endocrinol Metab. 1985; 61: 705–710.
30. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple 
methods for the estimation of free testosterone in serum. J Clin Endo-
crinol Metab 1999; 84: 3666–3672.
31. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone 
assay: are the results in men clinically useful? Clin Chem 1998; 44: 
2178–2182.
32. Morley JE, Patrick P, Perry III HM. Evaluation of assays available to 
measure free testosterone. Metabolism 2002; 51: 554–559.
33. Emadi-Konjin P, Bain J, Bromberg IL. Evaluation of an algorithm for 
calculation of serum “bioavailable” testosterone (BAT). Clin Biochem 
2003; 36: 591–596.
34. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement 
of total serum testosterone in adult men: comparison of current labora-
tory methods versus liquid chromatography-tandem mass spectrometry. 
J Clin Endocrinol Metab 2004; 89: 534–543.
35. Sikaris K, McLachlan RI, Kazlauskas R, de KD, Holden CA, Handelsman 
DJ. Reproductive hormone reference intervals for healthy fertile young 
men: evaluation of automated platform assays. J Clin Endocrinol Metab 
2005; 90: 5928–3596.
36. Taieb J, Mathian B, Millot F et al. Testosterone measured by 10 immunoas-
says and by isotope-dilution gas chromatography-mass spectrometry in 
sera from 116 men, women, and children. Clin Chem 2003; 49: 1381–1395.
37. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, 
and pitfalls in measuring testosterone: an Endocrine Society Position 
Statement. J Clin Endocrinol Metab 2007; 92: 405–413.
190
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Salivary androgens in polycystic ovary syndrome  Dorota Szydlarska et al.
38. Matsumoto AM, Bremner WJ. Serum testosterone assays: accuracy mat-
ters. J Clin Endocrinol Metab 2004; 89: 520–524.
39. Coffey JC, Crutchfield WC. In vitro metabolism of 4-androstene- 3,17-dione 
by human submaxillary gland homogenates. J Dent Res 1977; 56: 332–334.
40. Cardinali DP, Denari H, Rosner JM. In vitro metabolism of steroids by 
human and rabbit submaxillary glands. J Steroid Biochem 1971; 2: 67–76.
41. Booth WD. Metabolism of androgens in vitro by the submaxillary sali-
vary gland of the mature domestic boar. J Endocrinol 1977; 75: 145–154.
42. ElAttar TMA. In vitro metabolism of estrone 2,4,6,7-3H and 4-andros-
tene-3,17-dione-1,2-3H in submandibular gland and submandibular 
gland cancer tumor. Steroids 1974; 24: 519–526.
43. Blom T, Ojanotko-Harri A, Laine M, Huhtaniemi I. Metabolism of proges-
terone and testosterone in human parotid and submandibular salivary 
glands in vitro. J Steroid Biochem Mol Biol 1993; 44: 69–76.
44. Baxendale PM, Jacobs HS, James VHT. Salivary testosterone: relation-
ship to unbound plasma testosterone in normal and hyperandrogenic 
women. Clin Endocrinol 1982; 16: 595–603.
45. Sannikka E, Terho P, Suominen J, Santti R. Testosterone concentra-
tions in human seminal plasma and saliva and its correlation with 
non-protein-bound and total testosterone levels in serum. J Androl 
1983; 6: 319–330.
46. Wang C, Plymate S, Nieschlag E, Paulsen CA. Salivary testosterone in 
men: further evidence of a direct correlation with free serum testoster-
one. J Clin Endocrinol Metab 1981; 53: 1021–1024.
47. Baxendale PM, Reed MJ, James VHT. Testosterone in saliva of normal 
men and its relationship with unbound and total testosterone levels in 
plasma. J Endocrinol 1980; 87: 46–47.
48. Hammond GL, Langley MA. Identification and measurement of 
sex hormone binding globulin (SHBG) and corticosteroid bind-
ing globulin (CBG) in human saliva. Acta Endocrinol 1986; 112: 
603–608.
49. Wellen JJ, Smals AGH, Rijken JCW, Kloppenborg PWC, Benraad TM. Tes-
tosterone and 4-andi-ostenedione in saliva of patients with Klinefelter’s 
syndrome. Clin Endocrinol 1983; 18: 51–59.
